Salute e Benessere
Obesity Market to Observe Impressive Growth by 2034, Assesses DelveInsight | Key Companies - Novo Nordisk A/S, Pfizer, Boehringer Ingelheim, Eli Lilly and Company, Rhythm Pharmaceuticals, Harmony Biosciences
Discover which therapies are expected to grab major obesity market share @
Obesity is acknowledged as a chronic condition or noncommunicable ailment, characterized by a complex, multifaceted set of factors. It predominantly involves excessive body fat, along with being overweight, which can have metabolic implications beyond just physical size. Individuals grappling with obesity often face social and psychological stigma, leading to discrimination in various aspects of life, including personal relationships and employment, contributing to low self-esteem and depression. Childhood obesity can lead to similar health complications as adult obesity, sometimes even with an earlier onset.
The development of obesity is influenced by a combination of genetic predisposition and environmental factors. Certain severe and early-onset forms of obesity stem from mutations in genes related to the leptin-melanocortin axis, such as LEPR, POMC, MC4R, NTRK2, and SIM1. One of the most noticeable indicators of obesity is the accumulation of excess adipose tissue, typically assessed through anthropometric measurements. Common symptoms include stretch marks, high blood pressure, and a body mass index (BMI) exceeding 30 kg/m². Some symptoms can exacerbate, increasing the risk of developing various diseases and disorders.
According to DelveInsight's analyst, the diagnosed prevalent cases of obesity are on the rise, and as per the estimates, the United States accounted for of cases for adults (<19 years) and children (5–19 years), respectively, in 2023.
The obesity market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Weight reduction via nutritious eating, upping physical activity, and adopting lifestyle modifications are frequently employed treatments for obesity. Certain individuals might find weight management programs helpful for shedding excess weight or preventing its return. However, some obese individuals struggle to shed adequate weight to improve their well-being or to sustain their weight loss. In such cases, alternative therapies like weight-loss medications, devices, or bariatric surgery could be contemplated.
Alternative methods for obesity treatment include cutting-edge techniques. For instance, hydrogels are ingestible capsules containing tiny particles that soak up stomach water, triggering a sense of satiety. Vagal nerve blockade employs an implanted device beneath the skin of the abdomen to send electrical signals to the vagus nerve, signaling fullness to the brain. Gastric aspirate, a surgical intervention, involves placing a tube through the abdomen to remove a portion of stomach contents post-meals regularly. These varied approaches highlight the continuous progress in combating obesity.
FDA-approved treatments for obesity comprise , a blend of drugs that diminish appetite and cravings; , an injectable that curbs appetite and influences how quickly the stomach empties; , which obstruct pancreatic lipase to help manage obesity; , a prescription medication that suppresses appetite and fosters weight loss; , sanctioned for genetic-based obesity; and , an injectable drug that supports weight loss in adults with obesity or overweight when paired with a reduced-calorie diet and increased physical activity.
Learn more about the FDA-approved obesity drugs @
Some of the drugs in the obesity pipeline include , and others.
, known as , has received approval in the US, EU, and Japan as a complement to diet and exercise for enhancing glycemic control in adults with type II diabetes. It operates as an oral GLP-1 RA, mimicking the function of the natural hormone GLP-1. Additionally, the company is progressing in its development of this medication for treating obesity. Currently undergoing Phase III testing (NCT05564117; OASIS 4), the drug's safety and effectiveness are being assessed in individuals who are overweight or obese.
Activation of the glucagon-like peptide-1 receptor (GLP-1R) leads to decreased blood sugar levels and weight loss, offering a promising approach for managing Type II diabetes and obesity. has introduced , an oral GLP-1R agonist. In June 2023 , Pfizer declared its intention to advance danuglipron for further clinical evaluation as a potential treatment for obesity in adults. Subsequently, in December 2023 , Pfizer released initial findings from a Phase IIb clinical trial assessing danuglipron in obese adults without T2D. The trial successfully demonstrated a significant reduction in body weight compared to the baseline, marking a positive outcome for the study's primary objective.
The other late-stage therapies for obesity treatment in development include:
The anticipated launch of these emerging therapies for obesity are poised to transform the market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the obesity market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about drugs for obesity in development @
The dynamics of the obesity market are expected to change in the coming years. Pharmaceutical companies are i , with emerging mobile technologies offering unprecedented possibilities for understanding and intervening in obesity; key players like are addressing unmet needs in the obesity market, while work to raise awareness, expanding the market as patients seek treatment.
As many potential therapies are being investigated for the treatment of obesity, it is safe to predict that the treatment space will significantly impact the obesity market during the forecast period. Moreover, the with improved efficacy and a further are expected to drive the growth of the obesity market in the 7MM.
However several factors may impede the growth of the obesity market. There is on the best obesity treatment, as conventional medical interventions often fail in the long run for the great majority of obese individuals. Additionally, there is a in terms of disease staging systems used in the treatment landscape of obesity, highlighting the need to form a consensus on when or if to use different staging systems.
The comorbidities associated with obesity require additional medications and treatments, complicating obesity management, which leads to . Furthermore, obesity impacts the patient's quality of life, resulting in , imposing a threat to the market as the focus of patients shifts from obesity to its associated comorbidities such as diabetes, depression, and cardiovascular changes.
Moreover, obesity treatment poses a and disrupts patients' overall well-being and QOL. Furthermore, the obesity market growth may be offset by , , , and a . In addition, the about the disease may also impact the obesity market growth.
To know more about obesity treatment options, visit @
report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the obesity epidemiology trends.
report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key obesity companies, including , among others.
report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key hypothalamic obesity companies, including , among others.
report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products and the key hypothalamic obesity companies, including , among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
Shruti Thakur
info@delveinsight.com
+14699457679
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/obesity-market-to-observe-impressive-growth-by-2034-assesses-delveinsight--key-companies---novo-nordisk-as-pfizer-boehringer-ingelheim-eli-lilly-and-company-rhythm-pharmaceuticals-harmony-biosciences-302175060.html